logo-loader
Moneysupermarket.com

Moneysupermarket.com on track as first-quarter revenues rise 4%

More people switching their energy provider helped to drive the growth in the opening three months of the year, although commission from people switching banks fell

moneysupermarket advert
According to WebFG, analysts are expecting a pre-tax profit of £111.7mln on revenues of £346mln this year

Price comparison group Moneysupermarket.com Group PLC (LON:MONY) has told investors trading is on track after reporting a 4% rise in first-quarter revenues.

Total revenues rose to £88.3mln in the three months ended March 31 – in line with expectations and up from £85.0mln a year earlier.

Driving the growth was strong insurance switching which was underpinned by competitive pricing, while the home services division enjoyed growth in core energy switching.

Money switching revenues fell though, which Moneysupermarket said was due to fewer promotional products compared to the same period of 2017.

READ: Moneysupermarket downgraded by Citigroup

“Trading is on track in this year of transformation as we reinvent the business to help people save more money,” said chief executive Mark Lewis.

“We are expanding our product engineering hub in Manchester to improve the customer journeys on our sites and plan to unlock future growth with the agreement to acquire Decision Tech - a leader in home communications price comparison and white label B2B comparison services.”

Revenues for insurance rose 4% to £471.mln (Q1 17: £45.4mln), home services showed a 15% improvement to £11.5mln (Q1 17: £10mln), while money fell 1% to £23.1mln (Q1 17: £23.3mln).

Moneysupermarket said the board remains confident of hitting current market expectations in 2018.

Shares nudged 0.6%, or 1.8p, higher to 285.3p.

Quick facts: Moneysupermarket.com

Price: £3.66

Market: LSE
Market Cap: £1.96 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Open Orphan 'driving research for novel drug development for rare diseases'

Proactive London sits down with Open Orphan PLC's (LON:ORPH) chief operating officer Maurice Treacy. Treacy discusses how he became involved with Open Orphan and his ambitions for the firm's health data initiative. ''Many rare diseases aren't known or badly diagnosed ... but rare isn't...

13 hours, 50 minutes ago

RNS

Holding(s) in Company

12 hours, 36 minutes ago

Holding(s) in Company

12 hours, 38 minutes ago

Holding(s) in Company

6 days, 12 hours ago

Holding(s) in Company

1 week, 1 day ago

Holding(s) in Company

2 weeks, 1 day ago

Total Voting Rights

2 weeks, 1 day ago

Additional Listing

3 weeks, 5 days ago

2 min read